Compare CYTK & FROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | FROG |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.9B |
| IPO Year | 2004 | 2020 |
| Metric | CYTK | FROG |
|---|---|---|
| Price | $63.22 | $55.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 18 |
| Target Price | ★ $82.38 | $66.72 |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $87,211,000.00 | ★ $502,612,000.00 |
| Revenue This Year | $339.72 | $24.88 |
| Revenue Next Year | $79.08 | $16.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2609.26 | 22.69 |
| 52 Week Low | $29.31 | $27.00 |
| 52 Week High | $70.98 | $70.43 |
| Indicator | CYTK | FROG |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 37.91 |
| Support Level | $60.30 | $54.27 |
| Resistance Level | $65.35 | $58.78 |
| Average True Range (ATR) | 3.01 | 2.85 |
| MACD | -0.01 | -0.78 |
| Stochastic Oscillator | 57.11 | 13.47 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.